Medical Pharmacology: Diabetes Management Practice Questions
Click on the correct answer.
In patients with type
II diabetes, the leading cause of death:
Renal failure
Cardiovascular disease
Pulmonary hypertension
Liver failure
Diabetes mellitus effects about 415 million adults worldwide and is projected that by 2040 approximately 640 million adults will be diabetic.
True
False
Which one/ones of the following statements is/are correct?
Diabetic patients exhibit significant, high risk of adverse outcomes from renal disease, atherosclerotic heart disease, and heart failure.
High risk of heart failure in diabetic patients appears dependent on the presence of coronary disease.
Both
Neither
Dapagliflozin:
Classified as a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor.
Limits glucose resorption mainly at the loop of Henle.
Both
Neither
Use of SGLT2 inhibitors in diabetic patients without apparent existing atherosclerotic cardiovascular disease appears to prevent hospitalization for heart failure as well as decreased the likelihood of progression of kidney disease.
True
False
Administration of dapagliflozin to those type II diabetic patients at risk for atherosclerotic cardiovascular disease or had atherosclerotic cardiovascular disease:
Was not associated with a higher or lower rate of major adverse cardiovascular events (MACE) compared to placebo.
Was associated with a reduction in cardiovascular death or hospitalization for heart failure (as a result of decreased hospitalization rate for heart failure)
Both
Neither
Type II diabetes:
The leading cause of renal failure worldwide
Administration of sodium-glucose cotransporter 2 (SGLT2) inhibitors to diabetic patients may improve renal outcome.
Both
Neither
Compared to placebo, patients with type II diabetes and renal disease receiving canagliflozin appeared to have diminished risk of both kidney failure and cardiovascular events.
